Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,482,388 | $5,585,870 | $2,612,916 | $6,267,863 |
| - Cash | $102,014 | $71,286 | $119,709 | $209,948 |
| + Debt | $469,106 | $774,122 | $242,451 | $111,408 |
| Enterprise Value | $5,849,480 | $6,288,706 | $2,735,658 | $6,169,323 |
| Revenue | $508,824 | $249,380 | $204,036 | $180,080 |
| % Growth | 104% | 22.2% | 13.3% | – |
| Gross Profit | $488,661 | $236,584 | $186,223 | $162,146 |
| % Margin | 96% | 94.9% | 91.3% | 90% |
| EBITDA | $19,234 | -$470,356 | -$515,415 | -$628,299 |
| % Margin | 3.8% | -188.6% | -252.6% | -348.9% |
| Net Income | -$67,089 | -$506,984 | -$557,517 | -$644,085 |
| % Margin | -13.2% | -203.3% | -273.2% | -357.7% |
| EPS Diluted | -1.07 | -8.37 | -9.35 | -11.01 |
| % Growth | 87.2% | 10.5% | 15.1% | – |
| Operating Cash Flow | -$192,586 | -$436,847 | -$502,277 | -$298,653 |
| Capital Expenditures | -$4,630 | -$16,062 | -$8,919 | -$261,241 |
| Free Cash Flow | -$197,216 | -$452,909 | -$511,196 | -$559,894 |